Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

Novo Nordisk has filed another Citizen's Petition ... its GLP-1 and GIP agonist sold as Mounjaro for diabetes and Zepbound for obesity in the US. Lilly has filed to lend its support to the FDA ...

Wall Street major averages closed significantly higher on Friday, despite softer-than-expected inflation data, and consumer sentiment dropping to the second-lowest on record. Week-to-date, the U.S.

A bundle of healthcare legislation that would introduce greater oversight of the pharmacy benefit manager (PBM) sector is reported to be close to an agreement by US lawmakers. The package ...